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The principle aim of the sustainable development goal 3 is 
to improve equity of access to health care, which includes 
ending preventable deaths in neonates and children younger 
than 5 years (or achieving a reduction to at most 25 deaths per 
1000 live births) by 2030.1 More than half of deaths in children 
younger than 5 years are estimated to be due to infectious 
disease, with pneumonia being the leading cause.2 In addition, 
the authors of the World Health Organization’s WHO Model list 
of essential medicines for children,3 which was first published 
in 2007, state that reliable access to key medicines is vital for 
ensuring basic health-care needs are met.
Recently WHO announced its first specific target for 
combating antimicrobial resistance:4 Sixty percent of all anti-
biotics consumed in individual countries should come from 
the Access group of antibiotics (i.e. first- or second-choice 
empirical treatments for selected syndromes).3,5 The classifica-
tion of antibiotics into Access, Watch and Reserve categories 
(the AWaRe classification) was introduced by WHO in 2017 to 
combat antimicrobial resistance. In children, the main Access 
antibiotic is amoxicillin because WHO guidelines currently 
recommend oral amoxicillin as first-line therapy for suspected 
lower respiratory tract infection in those younger than 5 years.6 
Although differentiating viral and bacterial respiratory tract 
infections in children remains complex, a substantial propor-
tion of cases of bacterial childhood pneumonia worldwide are 
still not treated promptly with antibiotics. In addition, access 
to drugs on the model list for children remains limited in 
low- and middle-income countries.7
To explore current patterns of antibiotic use in children, 
we investigated sales of child-appropriate antibiotic formula-
tions. We defined a child-appropriate formulation as an oral 
formulation specifically designed for easy use in children 
that was either: (i) an oral liquid formulation; or (ii) an oral 
solid formulation that is dispersed in water or becomes liquid 
upon swallowing. Adult tablets were not included, as it has 
been shown that crushing (i.e. compounding) tablets to give 
to children can result in underdosing.8 Consumption of oral 
formulations was chosen as a proxy for child antibiotic use for 
several reasons. First, caregivers’ compliance with administer-
ing prolonged courses of oral antibiotics has been shown to 
correlate with the availability of liquid formulations.9 Second, 
data from studies of the palatability of different formulations 
of paediatric antiretroviral therapy indicate that most drugs 
consumed by children younger than 5 years are in a non-solid 
form.10,11 Third, the number of prescriptions for antibiotics 
dispensed in a liquid formulation has been shown to correlate 
with the number of children in a population.12
Amoxicillin, for example, is available in several child-
appropriate formulations, including granules, dispersible tablets 
and oral suspensions or syrups. Amoxicillin dispersible tablets 
have many advantages over oral suspensions and syrups: (i) they 
cost less; (ii) their volume is smaller because the weight per unit 
dose is lower, which means that less storage space is required in 
the supply chain; (iii) dosing is simpler; and (iv) refrigeration is 
unnecessary.13 Moreover, amoxicillin in dispersible tablet form 
was identified as one of 13 overlooked life-saving commodities 
by the United Nations Commission on Life-Saving Commodi-
ties in Women and Children.14 The commission promotes access 
to these commodities, which can prevent premature death in 
women and children, by encouraging innovations in product 
design and increased production. Over the past 5 years, the 
United Nations Children's Fund (UNICEF) has supported the 
large-scale procurement of amoxicillin dispersible tablets and 
the supply has increased more than 10-fold.13
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Objective To investigate international consumption patterns of child-appropriate oral formulations of antibiotics by formulation type, with 
a focus on dispersible tablets, using data from a global sales database.
Method Antibiotic sales data for 2015 covering 74 countries and regional country groups were obtained from the MIDAS® pharmaceutical 
sales database, which includes samples of pharmacy wholesalers and retailers. The focus was on sales of child-appropriate oral formulations 
of Access antibiotics in the 2017 World Health Organization’s WHO Model list of essential medicines for children. Sales volumes are expressed 
using a standard unit (i.e. one tablet, capsule, ampoule or vial or 5 mL of liquid). Sales were analysed by antibiotic, WHO region and antibiotic 
formulation.
Findings Globally, 17.7 billion standard units of child-appropriate oral antibiotic formulations were sold in 2015, representing 24% of total 
antibiotic sales of 74.4 billion units (both oral and parenteral) in the database. The top five child-appropriate Access antibiotics by sales 
volume were amoxicillin, amoxicillin with clavulanic acid, trimethoprim–sulfamethoxazole, cefalexin and ampicillin. The proportion of the top 
five sold for use as a syrup varied between 42% and 99%. Dispersible tablets represented only 22% of all child-appropriate oral formulation 
sales and made up only 15% of sales of 10 selected Access antibiotics on the model list for children.
Conclusion Globally most child-appropriate oral antibiotics were not sold as dispersible tablets in 2015, as recommended by WHO. There 
is a clear need for novel solid forms of antibiotics suitable for use in children.
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In 2018, WHO published the first 
method for a global antibiotic consump-
tion surveillance programme,15 which 
acknowledged that estimating paediatric 
antibiotic consumption was difficult be-
cause standardized daily defined dosages 
are not available for children. Currently 
there are no published estimates of the 
total annual volume of antibiotics sold 
for paediatric use that can be used to 
derive the proportion sold as dispers-
ible tablets and that can provide some 
estimate of the potential unmet need. 
Further, no published data exist on the 
consumption of dispersible tablets of 
antibiotics on the WHO Model list of 
essential medicines for children or on 
how consumption patterns of paediatric 
antibiotic formulations vary between 
WHO regions.16 The demand and supply 
of child-appropriate formulations are af-
fected by many factors; for example, the 
supply of trimethoprim–sulfamethoxa-
zole is subsidized by the Global Fund to 
Fight AIDS, Tuberculosis and Malaria in 
some regions.17
Data from the MIDAS® database 
(IQVIA, Durham, United States of 
America) on global pharmaceutical sales 
have previously been used to provide a 
broad overview of international trends 
in antibiotic sales and, by proxy, anti-
biotic consumption.18–20 The aim of our 
study was to investigate global consump-
tion patterns of child-appropriate oral 
formulations of antibiotics by formula-
tion type, with a focus on dispersible 
tablets. We used formulation-specific 
sales data from the MIDAS® database 
as a proxy for paediatric antibiotic con-
sumption and combined consumption 
data with demographic data from the 
United Nations to derive consumption 
per child.19,21,22
Methods
We obtained antibiotic sales data for 
2015 from the MIDAS® pharmaceutical 
sales database, which includes informa-
tion on sales from samples of pharmacy 
wholesalers and retailers in participat-
ing countries. The data included sales 
volumes (in standard units) through 
specific channels to pharmacies, drug 
outlets and hospitals, with the relative 
contributions of different channels to to-
tal sales varying between countries. No 
information on dosing or clinical indica-
tions was available to us. Data collected 
from Europe and North America were 
biased heavily towards procurement for 
public health-care systems, whereas data 
for other regions largely originated from 
the private sector. Although analyses 
show that market coverage can vary 
from 20 to 100% in contributing coun-
tries,18–21 the MIDAS® database provides 
one of the most comprehensive insights 
into global pharmaceutical sales patterns 
and has made a substantial contribution 
to the pharmacoepidemiology literature. 
Furthermore, data validation and qual-
ity assurance are carried out annually 
by IQVIA.23 
Pharmaceutical sales data are re-
ported in standard units, where a 
standard unit is equivalent to a single 
dose by volume (not by quantity of 
active ingredient): it can be one tab-
let, capsule, ampoule or vial or 5 mL 
of liquid.19,21 For example, a standard 
course of amoxicillin administered as 
one 5-mL teaspoon or one dispersible 
tablet given twice daily for 5 days would 
total 10 standard units. However, we 
were unable to determine from the sales 
data whether child-appropriate syrup 
formulations were actually consumed 
by children as they may also have been 
used by elderly people or by other adults 
unable to swallow solid formulations. 
Our primary data analysis included sales 
data on oral and parenteral antibiotics 
sold in 93 different formulations across 
74 countries and regional country 
groups. A secondary analysis focused 
on antibiotics on the 2017 WHO Model 
list of essential medicines for children. The 
database did not include information on 
nitrofurantoin.
We identified 22 child-appropriate 
oral antibiotic formulations covered by 
the MIDAS® database for inclusion in 
our study by independently selecting 
new form codes (available from the data 
repository).24 Formulation data held in 
the database are classified using new 
form codes, which were introduced by 
the European Pharmaceutical Market 
Research Association in 1986, in parallel 
with the Anatomical Therapeutic Chem-
ical classification system.25 Countries 
included in the database were grouped 
by WHO region: (i) two countries and 
one regional group in the African Re-
gion; (ii) 13 countries and one regional 
group in the Region of the Americas; 
(iii) six countries in the South-East 
Asia Region; (iv) 33 countries in the 
European Region; (v) nine countries 
in the Eastern Mediterranean Region; 
and (vi) 10 countries in the Western 
Pacific Region. In the African Region, 10 
countries were grouped as Francophone 
West Africa (i.e. Benin, Burkina Faso, 
Cameroon, Côte d'Ivoire, Democratic 
Republic of the Congo, Gabon, Guinea, 
Mali, Senegal and Togo) and, in the 
Region of the Americas, six countries 
were grouped as Central America (i.e. 
Costa Rica, El Salvador, Honduras, 
Guatemala, Nicaragua and Panama). 
The top five child-appropriate antibiotic 
formulations by sales volume in each 
WHO region were identified and the 
proportion of these top five formulations 
sold as dispersible tablets was calculated 
for each region.
Of the 22 child-appropriate oral 
antibiotic formulations identified, 10 
were Access antibiotics that were listed 
as a first- or second-line choice for treat-
ing clinical indications in the model list 
for children (Box 1).16 We analysed their 
sales in detail. Several of these formula-
tions require preparation before use, 
such as the addition of water; their new 
form code either starts with the letter D 
or E or is AAH or AAK.25 We also used 
these codes to determine the proportion 
of each antibiotic that was sold in the 
form of a dispersible tablet, solid tablet, 
liquid or granule or in another form.
We obtained estimates of the total 
population of each country from the 
MIDAS® data set and estimates of the 
population of children younger than 
5 years from the United Nations Popu-
lation Division data for 2015.22 Using 
these figures, we were able to calculate 
the number of standard units of each 
child-appropriate formulation sold per 
child younger than 5 years in each coun-
Box 1. Selected oral Access antibiotics, study of global consumption of child-appropriate 
antibiotic formulations, 2015
Beta-lactam antibiotics:
Amoxicillin; Ampicillin; Cefalexin; Cloxacillin; and Penicillin V
Other antibiotics:
Chloramphenicol; Clindamycin; Doxycycline; Metronidazole; and Trimethoprim–sulfamethoxazole
Note: All Access antibiotics (i.e. first- or second-choice empirical treatments for selected syndromes) listed 
were all included in the World Health Organization’s WHO Model list of essential medicines for children.3
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try. These were regarded as minimum 
consumption estimates because other 
important sources of antibiotics, for ex-
ample donors, were not included in the 
MIDAS® data set. All statistical analyses 
were carried out using RStudio v. 1.0.143 
(RStudio, Boston, USA).
Results
In 2015, 17.7 billion standard units of 
the 22 selected child-appropriate oral 
antibiotic formulations were sold in 
countries contributing to the MIDAS® 
data set out of a total of 74.4 billion stan-
dard units of all antibiotic formulations 
(i.e. oral and parenteral). Hence, child-
appropriate oral formulations accounted 
for 24% (17.8 billion/74.4 billion) of 
global antibiotic sales. Dispersible tablet 
sales accounted for 22% (4.0 billion/17.8 
billion) of all child-appropriate oral 
formulation sales, whereas 77% (13.6 
billion/17.8 billion) were in granule, 
powder or another form. The remainder 
were tablets that could be chewed or 
disperse in the mouth.
Fig. 1 shows the total volume of 
sales of the 22 selected child-appropriate 
oral antibiotic formulations in the six 
WHO regions and the percentage of 
those sales accounted for by dispers-
ible tablets. The total sales volume was 
highest in the South-East Asia Region 
and the proportion of sales attributable 
to dispersible tablets was highest in the 
South-East Asia and Western Pacific 
Regions (34%; 1.7 billion/5.0 billion; 
and 44%; 1.6 billion/3.6 billion, respec-
tively). The uptake of dispersible tablets 
was notably lower in the Region of the 
Americas and the Eastern Mediter-
ranean Region: the proportion of sales 
attributable to dispersible tablets was 1% 
(13.0 million/2.5 billion) and 3% (7.3 
million /2.7 billion) in these regions, 
respectively. Details of the five most 
commonly used child-appropriate anti-
biotic formulations in each WHO region 
are available from the data repository.24 
In particular, cefixime was widely used 
in the Western Pacific and South-East 
Asian Regions.
Fig. 2 shows the sales of the 22 se-
lected child-appropriate oral antibiotic 
formulations in individual countries in 
2015 and the percentage of those sales 
attributable to dispersible tablets. The 
highest sales of dispersible tablets were 
in China and India. Fig. 3 shows the 
sales per child in individual countries 
and the proportion of sales per child 
attributable to dispersible tablets. The 
median sales per child was 43 standard 
units (interquartile range: 26–59). The 
proportion of sales per child attributable 
to dispersible tablets varied widely be-
tween countries: the highest proportions 
were found in Algeria, Belgium, France, 
Greece and the Netherlands.
Table 1 shows that approximately 
10.1 billion standard units of child-
appropriate oral formulations of the 10 
Access antibiotics on the 2017 WHO 
Model list of essential medicines for chil-
dren were sold globally in 2015, which 
accounted for 56% (10.1 billion/17.8 
billion) of all child-appropriate oral an-
tibiotics formations sold. The majority 
were taken in liquid form, mostly con-
sumed as a syrup: 67% (6.8 billion/10.1 
billion) were sold as a powder and 
required the addition of water to make 
them ready for consumption, whereas 
15% (1.5 billion/10.1 billion) were sold 
as a ready-made syrup. Tablets that had 
to be dispersed in water accounted for 
only 16% (1.6 billion/10.1 billion) of 
sales. Overall, 78% (7.8 billion/10.1 
billion) of sales of child-appropriate 
formulations of the 10 Access antibiot-
ics were accounted for by amoxicillin 
and amoxicillin with clavulanic acid, 
generally for consumption as a liq-
uid. Trimethoprim–sulfamethoxazole, 
chloramphenicol and metronidazole 
were predominantly sold as ready-made 
syrups. In contrast, the non-β-lactams 
doxycycline and clindamycin were com-
monly sold as dispersible tablets.
Discussion
Our analysis shows that less than a quar-
ter of child-appropriate oral antibiotic 
formulation sales in 2015 globally were 
in the form of dispersible tablets. More-
over, two thirds were still sold as liquid 
formulations, which indicates that, by 
2015, liquids and powders requiring 
reconstitution had not fully replaced 
dispersible tablets, as recommended by 
WHO.6 Over three quarters of sales of 
the 10 child-appropriate formulations 
of Access antibiotics we investigated 
were of amoxicillin or amoxicillin with 
clavulanic acid.
The wide variation we found in the 
per-child consumption of child-appro-
priate antibiotic formulations (Fig. 3) 
may be the result of several factors. In 
particular, further research is needed to 
explore whether this variation reflects 
the appropriate clinical use of antibiotics 
(appropriateness could not be deter-
mined from MIDAS® data), the need 
for greater access to child-appropriate 
formulations or other system factors.
International comparisons of pae-
diatric antibiotic consumption face 
considerable challenges. Defining the 
appropriate sampling frame or the 
system level at which any measurement 
of consumption can be considered rep-
resentative of a country can be difficult. 
Many previous analyses of primary 
care or outpatients have assessed pre-
scriptions rather than consumption,26,27 
Fig. 1. Sales of child-appropriate oral antibiotics and the proportion sold as dispersible 
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WHO: World Health Organization.
Notes: Sales of 22 child-appropriate antibiotic formulations recorded on the MIDAS® database were 
included. A standard unit is equivalent to a single dose by volume: it can be one tablet, capsule, ampoule 
or vial or 5 mL of liquid.
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which reflects the difficulty of mea-
suring consumption. Nevertheless, a 
recent analysis of WHO data collected 
using service provision assessments and 
service availability and readiness assess-
ments confirms that the paediatric use 
of antibiotics in primary care is high for 
all clinical infections.28
For comparison, the MAL-ED study 
examined the number of courses of an-
tibiotics used in the community in 2134 
children younger than 2 years in eight 
countries: one site each in Bangladesh, 
Brazil, India, Nepal, Pakistan, Peru, 
South Africa and the United Republic 
of Tanzania.29 Bangladesh and Pakistan 
had the highest overall antibiotic con-
sumption per child (i.e. over 10 courses 
per year), whereas Brazil and South 
Africa had the lowest, with a 10-fold dif-
ference. In our study, we also found that 
of these eight countries, Pakistan had the 
highest annual consumption per child 
of child-appropriate antibiotic formu-
lations (Fig. 2). However, Bangladesh, 
Brazil and South Africa had very similar 
levels of consumption. The difference 
between the two studies was possibly 
due to differences in data collection and 
study population: (i) the MAL-ED study 
conducted active surveillance of antibi-
otic use, whereas the MIDAS® database 
recorded sales; and (ii) the MAL-ED 
study used defined study sites and age 
groups, whereas the MIDAS® database 
had a varying level of national coverage 
and used formulation-specific sales data 
as a proxy for consumption in children.
Our study aimed to provide a broad 
overview of the absolute volume of oral 
antibiotics sold in child-appropriate 
formulations across countries. However, 
the volumes reported here should be 
regarded as minimum estimates because 
the MIDAS® database does not cap-
ture data from some important global 
organizations. For example, UNICEF 
procured 193 million amoxicillin dis-
persible tablets in 2015,13 a substantial 
increase from 14 million in 2011. A 
complete analysis of the global market 
for oral antibiotics for children would 
need to include direct procurement 
by the public sector, donations from 
global organizations and sales in the 
informal sector. Our analysis should 
be considered as providing a baseline 
for paediatric antibiotic sales before 
implementation of the revised 2017 
WHO Model list of essential medicines 
for children, in which the AWaRe clas-
sification was introduced.3 Previously 
we investigated time trends in the use 
of child-appropriate antibiotic formu-
lations;21 although we found a slight 
change over time, no major fluctuations 
in global use from year to year were 
identified.
There is no clear evidence in the 
literature indicating, which antibiotic 
formulation is easiest to administer to 
children, most acceptable to children 
and families, and results in the best 
clinical outcomes.30 The key advantages 
of dispersible tablets are programmatic: 
(i) they require less space on transpor-
tation; (ii) they can be stored for pro-
longed periods; and (iii) their dosing is 
simpler than for liquid formulations or 
powders, which require doses to be mea-
sured before reconstitution. However, 
dispersible tablets have some disadvan-
tages, such as palatability. In addition, 
they require a clean water source (a typi-






























































































































































































































































































































SAR: Special Administrative Region.
Notes: Sales of 22 child-appropriate antibiotic formulations recorded on the MIDAS® database were included. A standard unit is equivalent to a single dose 
by volume: it can be one tablet, capsule, ampoule or vial or 5 mL of liquid. Francophone West Africa included Benin, Burkina Faso, Cameroon, Côte d'Ivoire, 
Democratic Republic of the Congo, Gabon, Guinea, Mali, Senegal and Togo and Central America included Costa Rica, El Salvador, Honduras, Guatemala, Nicaragua 
and Panama.
462 Bull World Health Organ 2020;98:458–466| doi: http://dx.doi.org/10.2471/BLT.19.235309
Research
Global consumption of paediatric antibiotics Grace Li et al.
Fig. 3. Sales of child-appropriate oral antibiotics per child younger than 5 years and the proportion sold as dispersible tablets, by 




































































































































































































































































































































SAR: Special Administrative Region.
Notes: Sales of 22 child-appropriate antibiotic formulations recorded on the MIDAS® database were included. A standard unit is equivalent to a single dose 
by volume: it can be one tablet, capsule, ampoule or vial or 5 mL of liquid. Francophone West Africa included Benin, Burkina Faso, Cameroon, Côte d'Ivoire, 
Democratic Republic of the Congo, Gabon, Guinea, Mali, Senegal and Togo and Central America included Costa Rica, El Salvador, Honduras, Guatemala, Nicaragua 
and Panama.
Table 1. Global sales of oral Access antibioticsa in child-appropriate formulations, by formulation, 2015
Antibiotic Sales volume,b no. of standard unitsc in millions (%)
Total Tablet Dispersible tablet Granule or 
powder
Ready-made syrup Syrup (sold in dry 
form)
Amoxicillin 4 256.0 (100) 55.6 (1) 918.1 (22) 71.8 (2) 299.9 (7) 2910.6 (68)
Amoxicillin with 
clavulanic acid
3 550.2 (100) 31.0 (1) 318.8 (9) 0.0 (0) 85.7 (2) 3114.8 (87)
Trimethoprim–
sulfamethoxazole
875.3 (100) 0.0 (0) 0.6 (< 1) 5.7 (< 1) 860.8 (98) 8.2 (1)
Cefalexin 650.7 (100) < 0.1 (< 0.1) 64.9 (10) 2.5 (< 1) 120.0 (18) 463.1 (71)
Ampicillin 251.9 (100) 0.0 (0) 145.6 (58) 0.0 (0) 15.4 (6) 90.2 (36)
Clindamycin 190.5 (100) 0.0 (0) 114.9 (60) < 0.1 (< 1) 0.8 (< 1) 74.8 (39)
Penicillin V 189.1 (100) 0.0 (0) 0.3 (< 1) 0.0 (0) 48.2 (26) 140.5 (74)
Chloramphenicol 100.3 (100) 0.0 (0) 0.7 (< 1) 0.0 (0) 99.6 (99) < 0.1 (< 1)
Doxycycline 58.0 (100) < 0.1 (< 1) 54.8 (95) 0.0 (0) 2.3 (4) 0.7 (1)
Cloxacillin 21.6 (100) 0.0 (0) 0.0 (0) 0.0 (0) 2.3 (11) 19.3 (89)
Metronidazole 1.2 (100) 0.0 (0) 0.0 (0) 0.0 (0) 1.2 (100) < 0.1 (0)
Total 10 145.0 (100) 86.6 (< 1) 1619.0 (16) 80.0 (< 1) 1536.3 (15) 6823.0 (67)
a  All Access antibiotics listed are first- or second-choice empirical treatments for selected syndromes and are included in the World Health Organization’s WHO Model 
list of essential medicines for children.3
b  Reported in the MIDAS® database.
c  A standard unit is equivalent to a single dose by volume: it can be one tablet, capsule, ampoule or vial or 5 mL of liquid.
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cal tablet needs 5 to 10 mL of water for 
dispersion) and caregivers must spend 
time waiting for the tablet to dissolve. In 
addition, an estimated 25% of the global 
disease burden in children younger than 
5 years is attributable to unsafe water, 
poor sanitation or inadequate hygiene,31 
which are being assessed by UN-Water 
and WHO as part of the sustainable 
development goal programme.32 Nev-
ertheless, recent evidence suggests that 
minitablets are tolerated by children 
as young as 2 months of age.30 Future 
research could focus on the development 
of oral-dispersible tablets or other forms 
of antibiotics that do not require water 
for administration, such as drugs that 
can be delivered through the transmu-
cosal route.33 Such developments could 
be facilitated by recent WHO initiatives, 
such as the Global Accelerator for Pae-
diatric Formulations,34 which is working 
in collaboration with the WHO Depart-
ment of Essential Medicines and Health 
Products and other key stakeholders, in-
cluding the Global Antibiotic Research 
and Development Partnership.
We acknowledge that the main limi-
tation of our study is its reliance on sales 
data from varying sources. However, 
the MIDAS® database provides detailed 
information on wholesale pharmacy 
sales of paediatric antibiotics in many 
countries and we know of no other 
database that can be used to compare 
the sales of child-appropriate antibiotic 
formulations internationally. Another 
limitation is that the MIDAS® database 
has a varying level of coverage of the 
public sector and of different supply 
channels, depending on region and the 
local health-care delivery structure. As 
paediatric medicines may be prioritized 
by publicly-funded health-care systems, 
it is difficult to predict, which supply 
channels will provide the most accurate 
data on child-appropriate formulation 
sales. In addition, data on sales, particu-
larly of dispersible tablets, in individual 
WHO regions may be dominated by a 
few large countries, such as China, India 
or the United States (Fig. 2).
In conclusion, our study used the 
largest available pharmaceutical sales 
data set to provide a baseline for the 
consumption of child-appropriate oral 
antibiotic formulations globally in 2015. 
We found that most of child-appropriate 
formulations sold globally in 2015 were 
not in a dispersible tablet form. Future 
efforts should focus on developing im-
proved solid forms of antibiotics suitable 
for use in children and encouraging 
their widespread use.35 ■
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مفلا قيرط نع لافطلأل ةيويلحا تاداضملل ةيلماعلا تاعيبلما
 ةبسانلما  تابيكترلل  ليودلا  كلاهتسلاا  طمانأ  ءاصقتسا  ضرغلا
 ،بيكترلا عون بسح ،مفلا قيرط نع لافطلأل ةيويلحا تاداضملل
 نم تانايبلا مادختسابو ،راشتنلال ةلباقلا صارقلأا لىع زيكترلا عم
.ةيلماعلا تاعيبلما تانايب ةدعاق
 ماعل ةيويلحا تاداضلما تاعيبم تانايب لىع لوصلحا مت ةقيرطلا
 ةدعاق نم ،ةيميلقإ لود تاعوممجو ةلود 74 يطغت يتلاو ،2015
 نم تانيع لمشت يتلاو ،MIDAS® ةينلاديصلا تاعيبلما تانايب
 تاعيبم  لىع زيكترلا  ناك  .تايلديصلل  ةئزجتلا  راتجو ةلملجا  راتج
 ةيويلحا تاداضلما نم لافطلأل مفلا  قيرط نع ةبسانلما  تابيكترلا
 لافطلأل ةيساسلأا ةيودلأل ةيجذومنلا ةمئاقلا في لوانتلما في ةحاتلما
 يربعتلا  متي  .2017ماع  (WHO)  ةيلماعلا  ةحصلا  ةمظنلم  ةعباتلا
 ،دحاو  صرق  يأ)  ةيسايق  ةدحو  مادختساب  تاعيبلما  ماجحأ  نع
 نم لم 5 وأ ،ةدحاو ةنينق وأ ،دحاو لوبمأ وأ ،ةدحاو ةلوسبك وأ
 ةمظنم ةقطنمو ،يويلحا داضملل ًاعبت تاعيبلما ليلتح متو .(لئاسلا
.يويلحا داضلما بيكرتو ،ةيلماعلا ةحصلا
 ةيسايق ةدحو رايلم 17.7 عيب مت ،يلماعلا ديعصلا لىع جئاتنلا
 ماع مفلا قيرط نع لافطلأل ةبسانلما ةيويلحا تاداضلما تابيكرت نم
 ةيويلحا  تاداضلما  تاعيبم  لياجمإ  نم 24٪  لثمي  ام  وهو ،2015
 (نقلحاب  وأ  مفلا  قيرط  نع  ءاوس)  ةدحو  رايلم  74.4  غلبت  يتلا
 ،لىولأا  ةسملخا  ةيويلحا  تاداضلما  تناك  .تانايبلا  ةدعاق  في
 تاعيبلما  مجح  بسح  ،لافطلأل  ةبسانلماو  لوانتلما  في  ةحاتلما
 ،كينلاوفلاك  ضحم  عم  ينليسيسكومأو  ،ينليسيسكومأ  :يه
 .ينليسيبمأو  ،ينسكيلافيسو  ،لوزاسكوثيمافلس  ميربوثيميارتو
 42٪ ينب باشرك مادختسلال ًاعيبم رثكلأا ةسملخا ةبسن تحوارتو
 نم طقف 22٪  لثتم راشتنلال ةلباقلا  صارقلأا تناك مانيب  .99٪و
 تلكشو ،مفلا قيرط نع لافطلأل ةبسانلما تابيكترلا تاعيبم عيجم
 ،لوانتلما في ةحاتلما ةيويلحا تاداضلما نم 10 تاعيبم نم طقف 15٪
.لافطلأل ةيجذومنلا ةمئاقلا في ةراتخلما
 لافطلأل ةبسانلما ةيويلحا تاداضلما مظعم عيب متي لم جاتنتسلاا
 ماع في راشتنلال ةلباق صارقأك لماعلا ىوتسم لىع مفلا قيرط نع
 كانه  .(WHO)  ةيلماعلا  ةحصلا  ةمظنم  تصوأ  ماك  ،2015
 ةبسانلما ةيويلحا تاداضلما نم ةديدج ةبلص لاكشلأ ةحضاو ةجاح
.لافطلأا ةطساوب مادختسلال
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抗生素、世界卫生组织地区和抗生素剂型对销售情况
进行分析。













Ventes mondiales d'antibiotiques à usage oral destinés aux enfants
Objectif Étudier la consommation internationale d'antibiotiques à 
usage oral destinés aux enfants en fonction du type de formulation, en 
mettant l'accent sur les comprimés dispersibles. Et ce, en utilisant les 
données issues d'une base de données mondiale relative aux ventes.
Méthodes Les informations sur la vente d'antibiotiques en 2015 
dans 74 pays et groupes régionaux de pays proviennent de la base de 
données de ventes pharmaceutiques MIDAS®, qui inclut des échantillons 
de grossistes et détaillants de produits pharmaceutiques. La priorité 
était accordée aux antibiotiques à usage oral destinés aux enfants 
dont l'accessibilité est essentielle (Access), conformément à l'édition 
2017 de la Liste modèle des médicaments essentiels destinés à l'enfant 
de l'Organisation mondiale de la Santé (OMS). Les volumes de vente 
sont exprimés selon une unité de mesure standard (c'est-à-dire un 
comprimé, une capsule, une ampoule ou flacon, ou 5 ml de liquide). 
Les ventes ont été analysées pour chaque antibiotique, région OMS et 
formulation d'antibiotique.
Résultats À l'échelle mondiale, 17,7 milliards d'unités standard 
d'antibiotiques à usage oral destinés aux enfants ont été écoulées en 
2015, ce qui équivaut à 24% du volume total de vente d'antibiotiques 
(74,4 milliards d'unités, tant par voie orale que parentérale) que 
contient la base de données. Les cinq principaux antibiotiques Access 
administrés aux enfants étaient l'amoxicilline, l'amoxicilline + acide 
clavulanique, le sulfaméthoxazole + triméthoprime, la céfalexine et 
l'ampicilline. Le pourcentage de vente pour ces cinq antibiotiques, 
commercialisés sous forme de sirop, était compris entre 42% et 99%. Les 
comprimés dispersibles ne représentaient que 22% de l'ensemble des 
formulations à usage pédiatrique, et seulement 15% des ventes pour 
les 10 antibiotiques Access sélectionnés dans la liste modèle.
Conclusion La plupart des antibiotiques administrés par voie orale aux 
enfants n'étaient pas vendus sous forme de comprimés dispersibles en 
2015 dans le monde, contrairement aux recommandations de l'OMS. 
Il est donc nécessaire de développer de nouvelles formes solides 
d'antibiotiques, adaptées à un usage pédiatrique.
Резюме
Продажи пероральных детских лекарственных форм антибиотиков в мире
Цель Исследование глобальных моделей потребления 
пероральных детских лекарственных форм антибиотиков с 
уделением особого внимания диспергируемым таблеткам с 
помощью сведений из глобальной базы данных о продажах.
Методы Данные о продажах антибиотиков в 74 странах мира 
и региональных группах стран за 2015 год были получены из 
базы данных продаж фармацевтической продукции MIDAS®, 
содержащей данные по оптовым и розничным аптекам. 
Основное внимание уделялось продажам пероральных детских 
лекарственных форм антибиотиков из группы массовой 
доступности (согласно Примерному перечню Всемирной 
организации здравоохранения (ВОЗ) основных лекарственных 
средств для детей на 2017 год). Объемы продаж были выражены 
в стандартных единицах (то есть одна таблетка, капсула, ампула 
или флакон либо 5 мл жидкости). Анализ продаж осуществлялся 
по антибиотикам, региону ВОЗ и лекарственным формам.
Результаты В 2015 году в мире было продано 17,7 млрд 
стандартных единиц пероральных лекарственных форм 
антибиотиков, приемлемых для детей, что составляет 24% от 
общего объема продаж антибиотиков (74,4 млрд единиц как 
пероральных, так и парентеральных лекарственных форм), 
зарегистрированного в базе данных. В пятерку лидеров по объемам 
продаж детских антибиотиков из группы массовой доступности 
вошли амоксициллин, амоксициллин + клавулановая кислота, 
триметоприм/сульфаметоксазол, цефалексин и ампициллин. 
Доля продаж пяти лидеров в виде сиропа варьировалась от 42 до 
99%. Диспергируемые таблетки составляли лишь 22% от общего 
объема продаж пероральных детских лекарственных форм и 
всего 15% от общего объема продаж 10 выбранных антибиотиков 
из группы массовой доступности Примерного перечня основных 
лекарственных средств для детей.
Вывод В 2015 году во всем мире большинство приемлемых 
для детей пероральных лекарственных форм антибиотиков не 
продавались в форме диспергируемых таблеток, как это было 
рекомендовано ВОЗ. Существует явная необходимость в выпуске 
новых твердых лекарственных форм антибиотиков, подходящих 
для применения у детей.
Resumen
Ventas mundiales de los antibióticos de uso oral para niños
Objetivo Investigar los patrones de consumo internacional de las 
formulaciones pediátricas orales apropiadas de los antibióticos según 
el tipo de formulación, con énfasis en los comprimidos dispersables 
y mediante el uso de la información de una base de datos de ventas 
mundiales.
Métodos Los datos sobre las ventas de antibióticos correspondientes a 
2015, que abarcan 74 países y grupos regionales de países, se obtuvieron 
de la base de datos sobre las ventas de los productos farmacéuticos 
MIDAS®, que incluye muestras de mayoristas y de minoristas de 
farmacias. El enfoque se centró en la venta de las formulaciones 
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pediátricas orales apropiadas de los antibióticos del Grupo de acceso 
(Access) de la Lista modelo de medicamentos pediátricos esenciales de 
2017 de la Organización Mundial de la Salud (OMS). Las cantidades 
que se venden se expresan en una unidad estándar (es decir, un 
comprimido, una cápsula, una ampolla, un vial o 5 ml de líquido). Las 
ventas se analizaron por antibiótico, región de la OMS y formulación 
del antibiótico.
Resultados A nivel mundial, se vendieron 17 700 millones de unidades 
estándar de formulaciones pediátricas apropiadas de antibióticos orales 
en 2015, lo que representa el 24 % de las ventas totales de antibióticos 
de 74 400 millones de unidades (tanto por vía oral como parenteral) 
en la base de datos. Los cinco antibióticos principales del Grupo de 
acceso apropiados para niños según la cantidad que se vendió fueron 
la amoxicilina, la amoxicilina con ácido clavulánico, la trimetoprima-
sulfametoxazol, la cefalexina y la ampicilina. El porcentaje de los cinco 
antibióticos más vendidos para su uso como jarabe varió entre el 42 % 
y el 99 %. Los comprimidos dispersables representaron solo el 22 % de 
todas las formulaciones pediátricas orales apropiadas que se vendieron y 
representaron solo el 15 % de las ventas de los 10 antibióticos del Grupo 
de acceso elegidos de la lista modelo pediátrica.
Conclusión La mayoría de los antibióticos orales apropiados para los 
niños no se vendieron en forma de comprimidos dispersables en 2015 
a nivel mundial, como recomendó la OMS. Es evidente la necesidad 
de desarrollar nuevas formas sólidas de antibióticos adecuados para 
su uso pediátrico.
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